T1	Condition 16 32	hypersensitivity
T2	Drug 40 50	study drug
R1	AND Arg1:T1 Arg2:T2	
T3	Condition 63 71	diabetes
T4	Condition 81 94	liver disease
T5	Qualifier 74 80	Severe
R2	Has_qualifier Arg1:T4 Arg2:T5	
T6	Measurement 113 116	AST
T7	Measurement 106 109	ALT
T8	Value 116 148	=2.5-fold the normal upper limit
T9	Condition 151 170	biliary obstruction
*	OR T7 T6
T10	Scope 106 116	ALT or AST
R3	Has_value Arg1:T10 Arg2:T8	
T11	Scope 74 94	Severe liver disease
R4	Subsumes Arg1:T11 Arg2:T10	
R5	AND Arg1:T11 Arg2:T9	
T12	Drug 196 208	cyclosporine
T13	Procedure 181 190	treatment
T14	Temporal 173 180	Ongoing
R6	Has_temporal Arg1:T13 Arg2:T14	
R7	AND Arg1:T13 Arg2:T12	
T15	Temporal 209 223	within 2 weeks
R8	Has_temporal Arg1:T13 Arg2:T15	
T16	Condition 226 243	Renal dysfunction
T17	Measurement 255 286	endogenous creatinine clearance
T18	Person 287 291	male
A1	Optional T18
T19	Person 303 309	female
A2	Optional T19
T20	Value 309 319	<105ml/min
T21	Value 291 301	<120ml/min
R9	Has_value Arg1:T18 Arg2:T21	
R10	Has_value Arg1:T19 Arg2:T20	
*	OR T18 T19
T22	Measurement 321 337	serum creatinine
T23	Value 337 344	=2mg/dl
T24	Value 346 355	186umol/L
R11	Subsumes Arg1:T23 Arg2:T24	
R12	Has_value Arg1:T22 Arg2:T23	
T25	Measurement 358 372	Renal function
T26	Value 373 392	progressive decline
R13	Has_value Arg1:T25 Arg2:T26	
T27	Measurement 394 397	GFR
T28	Value 397 416	<30ml•min-1•1.73m-2
R14	Has_value Arg1:T27 Arg2:T28	
T29	Scope 287 319	male<120ml/min, female<105ml/min
R15	Has_scope Arg1:T17 Arg2:T29	
*	OR T17 T22 T25 T27
T30	Scope 255 416	endogenous creatinine clearance male<120ml/min, female<105ml/min, serum creatinine=2mg/dl (186umol/L), Renal function progressive decline, GFR<30ml•min-1•1.73m-2
R16	Subsumes Arg1:T16 Arg2:T30	
T31	Condition 448 453	ASCVD
T32	Condition 465 468	ACS
T33	Condition 470 474	SCAD
T34	Procedure 476 493	revascularization
T35	Condition 495 498	ICM
T36	Condition 500 515	ischemic stroke
T37	Condition 517 520	TIA
T38	Condition 522 526	PASD
*	OR T38 T37 T36 T35 T34 T33 T32
T39	Scope 465 526	ACS, SCAD, revascularization, ICM, ischemic stroke, TIA, PASD
R17	Subsumes Arg1:T31 Arg2:T39	
T40	Measurement 534 537	SBP
T41	Measurement 550 553	DBP
T42	Value 537 545	=180mmHg
T43	Value 553 561	=110mmHg
R18	Has_value Arg1:T40 Arg2:T42	
R19	Has_value Arg1:T41 Arg2:T43	
*	OR T41 T40
T44	Drug 587 600	Beta blockers
T45	Temporal 564 571	Ongoing
T46	Procedure 572 581	treatment
T47	Drug 602 610	Diuretic
*	OR T47 T44
T48	Scope 587 610	Beta blockers, Diuretic
R20	Has_temporal Arg1:T46 Arg2:T45	
R21	Has_scope Arg1:T46 Arg2:T48	
T49	Condition 613 635	Secondary hypertension
T50	Condition 647 650	SAS
T51	Condition 652 654	PA
T52	Condition 656 659	RAS
T53	Condition 661 677	pheochromocytoma
T54	Condition 679 697	Cushing's syndrome
T55	Condition 699 713	aorta diseases
T56	Condition 728 740	hypertension
T57	Qualifier 715 727	drug induced
R22	Has_qualifier Arg1:T56 Arg2:T57	
*	OR T55 T54 T56 T53 T52 T51 T50
T58	Scope 647 740	SAS, PA, RAS, pheochromocytoma, Cushing's syndrome, aorta diseases, drug induced hypertension
R23	Subsumes Arg1:T49 Arg2:T58	
T59	Drug 766 773	statins
T60	Drug 775 783	fibrates
T61	Temporal 743 750	Ongoing
T62	Procedure 751 760	treatment
T63	Drug 792 814	cation exchange resins
T64	Temporal 815 829	within 2 weeks
*	OR T60 T63 T59
T65	Scope 766 814	statins, fibrates, and/or cation exchange resins
R24	Has_temporal Arg1:T62 Arg2:T61	
R25	Has_scope Arg1:T62 Arg2:T65	
R26	Has_temporal Arg1:T62 Arg2:T64	
T66	Condition 832 850	Pancreatic disease
T67	Procedure 864 875	gastrectomy
T68	Condition 877 897	short bowel syndrome
T69	Observation 853 860	History
*	OR T68 T67
T70	Scope 864 897	gastrectomy, short bowel syndrome
R27	Has_temporal Arg1:T70 Arg2:T69	
T71	Temporal 900 907	Ongoing
T72	Procedure 908 935	hormone replacement therapy
R28	Has_temporal Arg1:T72 Arg2:T71	
T73	Condition 961 976	malignant tumor
T74	Mood 951 960	suspected
T75	Mood 938 947	Diagnosed
*	OR T74 T75
T76	Scope 938 960	Diagnosed or suspected
R29	Has_scope Arg1:T73 Arg2:T76	
T77	Condition 979 1008	Familial hypercholesterolemia
T78	Non-query-able 1011 1069	Any diseases may limit the efficacy or safety of the study
T79	Pregnancy_considerations 1072 1198	Pregnant or possibly pregnant woman, or breastfeeding woman, or woman who wishes to become pregnant during study participation
T80	Non-representable 1201 1870	IFG impaired fast glucose, FPG fasting plasma glucose, IGT impaired glucose tolerance, OGTT oral glucose tolerance test, PG plasma glucose, HbA1C hemoglobin A1C, LDL-C low-density lipoprotein cholesterol, TG triglycerides, SBP systolic blood pressure, DBP diastolic blood pressure, ALT alanine aminotransferase, AST aspartate aminotransferase, GFR glomerular filtration rate, ASCVD arteriosclerotic cardiovascular disease, ACS acute coronary syndrome, SCAD stable coronary artery disease, ICM ischemic cardiomyopathy, TIA transient ischemic attack, PASD peripheral atherosclerotic disease, SAS sleep apnea syndrome, PA primary aldosteronism, RAS renal arterial stenosis
